1. Turning genes into medicines—what have we learned from gene therapy drug development in the past decade?
2. Gottlieb S. Statement from FDA commissioner Scott Gottlieb M.D. and Peter Marks M.D. Ph.D. director of the center for biologics Evaluation and research on new policies to advance development of safe and effective cell and gene therapies [Internet]. FDA; 2019 [cited 2023 Apr 25]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics
3. FDA Office of Tissues and Advanced Therapies (OTAT). Approved cellular and gene therapy products [Internet]. FDA. FDA; 2023 [cited 2023 Apr 25]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
4. Food and Drug administration: statement of organization, functions, and delegations of authority;Becerra X.;Fed Regist,2022
5. Chemistry Manufacturing and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Guidance for industry. Docket Number 2008-D-0205. [Internet]. U.S. Departent of Health and Human Services Food and Drug Adminstration. Center for Biologics Evaluation and Research; 2020 [cited 2023 Apr 18]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug